Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3/NF-κB pathway in mice.

Qinyu WangYangjie OuGuomin HuCong WenShanshan YueCong ChenLu XuJiawei XieHui DaiHan XiaoYouyi ZhangRong Qi

Published in: British journal of pharmacology (2020)

Naringenin prevented NAFLD via down-regulating the NLRP3/NF-κB signalling pathway both in KCs and in hepatocytes, thus attenuating inflammation in the mice livers.

Keyphrases

oxidative stress
signaling pathway
lps induced
high fat diet induced
pi k akt
nuclear factor
inflammatory response
insulin resistance
liver injury
metabolic syndrome
liver fibrosis